| Schedule of Earnings Per Share, Basic and Diluted |
The following table summarizes the Company’s computation of basic and diluted net income (loss) per share available to common stockholders for the three months ended March 31, 2026 and 2025: | | | | | | | | | | | | | | | | Three Months Ended March 31, | | | 2026 | | 2025 | Numerator: | | | | | | | Net income (loss) | | $ | 5,686 | | $ | (5,688) | Less: Earnings allocated to participating securities | | | | | | | Accumulated undeclared dividends – Series A | | | (2,664) | | | — | Accumulated undeclared dividends – Series B | | | (2,283) | | | — | Allocable net income (loss) | | | 739 | | | (5,688) | Allocation of undistributed earnings – Series A | | | (199) | | | — | Allocation of undistributed earnings – Series B | | | (185) | | | — | Net income (loss) available to common stockholders | | $ | 355 | | $ | (5,688) | Denominator: | | | | | | | Weighted average common shares outstanding – basic and diluted | | | 5,455 | | | 4,618 | Net income (loss) per common share available to common stockholders – basic and diluted | | $ | 0.07 | | $ | (1.23) |
|
The following tables summarizes the Company’s computation of basic and diluted net loss per share attributable to common stockholders for the years ended December 31, 2025 and 2024: | | | | | | | | | | | | | | | | Year Ended December 31, | | | 2025 | | 2024 | Numerator: | | | | | | | Net income (loss) | | $ | 1,365 | | $ | (25,915) | Accumulated undeclared dividends on series A preferred stock | | | (1,035) | | | — | Accumulated undeclared dividends on series B preferred stock | | | (887) | | | — | Net loss attributable to common stockholders | | $ | (557) | | $ | (25,915) | Denominator: | | | | | | | Weighted average common shares outstanding | | | | | | | – basic and diluted | | | 5,027 | | | 4,347 | Net loss per share attributable to common stockholders | | | | | | | – basic and diluted | | $ | (0.11) | | $ | (5.96) |
|
| Schedule of Antidilutive Securities |
The following table summarizes potential common shares outstanding at each period end that were excluded from diluted net income (loss) per share because their effect would have been anti-dilutive: | | | | | | | | | | | | Three Months Ended March 31, | | | 2026 | | 2025 | Public warrants | | 500,000 | | 500,000 | Private warrants | | 13,300 | | 13,300 | Stock options | | 255,189 | | 270,554 | Unvested restricted stock units | | 83,396 | | 203,714 | Shares issuable upon Series A and Series B Preferred Stock Conversion | | 5,891,471 | | — | Total potential common shares excluded | | 6,743,356 | | 987,568 |
|
The following table summarizes potential common shares outstanding at each period end that were excluded from diluted net loss per share because their effect would have been anti-dilutive: | | | | | | | | | | | | Year Ended December 31, | | | 2025 | | 2024 | Public warrants | | 500,000 | | 500,000 | Private warrants | | 13,300 | | 13,300 | Stock options | | 255,189 | | 270,554 | Unvested restricted stock units | | 115,758 | | 264,812 | Shares issuable upon Series A and Series B Preferred Stock Conversion | | 5,636,650 | | — | Total common stock equivalents | | 6,520,897 | | 1,048,666 |
|